- Home
- SLMT vs CCCC Comparison
SLMT vs CCCC Comparison
Compare SLMT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLMT | CCCC |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.9M | 177.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SLMT | CCCC |
|---|---|---|
| Price | $1.18 | $1.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | ★ 943.9K | 874.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,584,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 71.44 |
| 52 Week Low | $0.99 | $1.09 |
| 52 Week High | $24.05 | $3.64 |
Technical Indicators
Market Signals| Indicator | SLMT | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 35.86 | 47.80 |
| Support Level | $0.99 | $1.79 |
| Resistance Level | $1.32 | $1.97 |
| Average True Range (ATR) | 0.16 | 0.13 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 34.58 | 68.56 |
Price Performance
Historical ComparisonAbout SLMT Brera Holdings PLC Class B Ordinary Shares
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.